Literature DB >> 31292516

Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia.

Longzhen Cui1,2,3,4, Yan Liu2, Yifan Pang5, Tingting Qian1,4, Liang Quan1,4, Zhiheng Cheng6, Yifeng Dai7, Xu Ye1, Ying Pang1, Jinlong Shi8, Xiaoyan Ke9, Depei Wu10, Lin Fu11,12,13.   

Abstract

Relapsed and refractory acute myeloid leukemia (R/R AML) has complicated pathogenesis. Its treatment is complicated, and the prognosis is poor. So far, there is no consensus on what is the optimal treatment strategy. With the deepening of research, new chemotherapy regimens, new small molecule inhibitors, and immunotherapy have been increasingly applied to clinical trials, providing more possibilities for the treatment of R/R AML. The most effective treatment for patients who achieve complete remission after recurrence is still sequential conditioning therapy followed by allogeneic hematopoietic cell transplantation. Finding the best combination of treatments is still an important goal for the future.

Entities:  

Mesh：

Year:  2019        PMID： 31292516     DOI： 10.1038/s41417-019-0119-5

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN： 0929-1903            Impact factor:   5.987


  124 in total

Review 1.  Acute myeloid leukemia.

Authors:  B Löwenberg; J R Downing; A Burnett
Journal:  N Engl J Med       Date:  1999-09-30       Impact factor: 91.245

2.  [Essential senile bulimia].

Authors:  A Castellani
Journal:  Arch Ital Sci Med Trop Parassitol       Date:  1971 Jul-Dec

3.  Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study.

Authors:  F Thalhammer; K Geissler; U Jäger; P A Kyrle; I Pabinger; M Mitterbauer; H Gisslinger; P Knöbl; K Laczika; B Schneider; O A Haas; K Lechner
Journal:  Ann Hematol       Date:  1996-04       Impact factor: 3.673

4.  Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen.

Authors:  D W Sternberg; W Aird; D Neuberg; L Thompson; K MacNeill; P Amrein; L N Shulman
Journal:  Cancer       Date:  2000-05-01       Impact factor: 6.860

5.  A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties.

Authors:  K Wheatley; A K Burnett; A H Goldstone; R G Gray; I M Hann; C J Harrison; J K Rees; R F Stevens; H Walker
Journal:  Br J Haematol       Date:  1999-10       Impact factor: 6.998

6.  Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.

Authors:  Emmanuelle Tavernier; Quoc-Hung Le; Mohamed Elhamri; Xavier Thomas
Journal:  Leuk Res       Date:  2003-03       Impact factor: 3.156

7.  Response to salvage therapy and survival after relapse in acute myelogenous leukemia.

Authors:  M J Keating; H Kantarjian; T L Smith; E Estey; R Walters; B Andersson; M Beran; K B McCredie; E J Freireich
Journal:  J Clin Oncol       Date:  1989-08       Impact factor: 44.544

8.  Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse.

Authors:  A Weltermann; C Fonatsch; O A Haas; H T Greinix; P Kahls; G Mitterbauer; U Jäger; B Kainz; K Geissler; P Valent; W R Sperr; P Knöbl; I Schwarzinger; A Gleiss; K Lechner
Journal:  Leukemia       Date:  2004-02       Impact factor: 11.528

9.  Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison.

Authors:  W Kern; C Aul; G Maschmeyer; R Schönrock-Nabulsi; W D Ludwig; A Bartholomäus; P Bettelheim; B Wörmann; T Büchner; W Hiddemann
Journal:  Leukemia       Date:  1998-07       Impact factor: 11.528

10.  Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center.

Authors:  R B Walter; M Othus; A K Burnett; B Löwenberg; H M Kantarjian; G J Ossenkoppele; R K Hills; F Ravandi; T Pabst; A Evans; S R Pierce; M-C Vekemans; F R Appelbaum; E H Estey
Journal:  Leukemia       Date:  2014-08-12       Impact factor: 11.528
View more
  1 in total

1.  Homo sapiens circular RNA 0003602 (Hsa_circ_0003602) accelerates the tumorigenicity of acute myeloid leukemia by modulating miR-502-5p/IGF1R axis.

Authors:  Qidong Ye; Nan Li; Kai Zhou; Cong Liao
Journal:  Mol Cell Biochem       Date:  2022-01-06       Impact factor: 3.396
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.